Strategic Analysis of the European Therapeutic Monoclonal Antibodies (Non-Cancer) Market


  • Research Code : 3884-01-00-00-00
  • SKU : HC00064-EU-MR_02757
  • Share this :
  • Release Date : 08-Apr-2003
  • Region : Europe
  • Request Study Sample

Availability: In stock

This report will address the products and molecules currently in phase II to launch phase and their potential applications in the segments highlighted below. It will include products that Frost & Sullivan predict will be launched within the forecast period of 2002 to 2010. The success of a product through phase III trials is obviously not guaranteed, with around a 30 percent failure rate. Therefore, this report must be based on a number of assumptions, all of which will be highlighted throughout. Products already available on the market, as well as competitive situation will be addressed. Each segment will be researched on a European level, with any specific country challenges and trends identified.
USD 4,950

* Required Fields

Pay By Invoice

Be the first to review this product

Related Research

1. Primary Research

Our analysis is based on comprehensive primary research conducted with core market participants.

2. Global Coverage

Unparalleled coverage of geographies, our analyst & consultant teams are based in 42+ offices spanning the globe.

3. Breadth of Vertical Industries

We cover the broadest spectrum of markets to provide our clients with the most relevant analysis and transformational insights.

4. Visionary Innovation Research

With on-going transformational shifts, our visionary innovation research prepares you with information on key megatrends shaping the future of your industry.

5. Mega Trends

Mega Trends are global forces that transform business, societies and economies.

6. Convergence Research Coverage

Taking an approach of analysing a macro-to-micro impact, our convergence research helps you prepare against an impending 'Kodak moment'.